Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07155174 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

A Phase 2 study of Small-cell Lung Cancer, sponsored by AbbVie.

Recruiting
Registry status
Phase 2
Development phase
180
Enrollment target
16
Study locations

NCT07155174 is a Phase 2 study of Small-cell Lung Cancer that is actively recruiting participants, run by AbbVie. The registered enrollment target is 180 participants, below the 230-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (22% lower). The trial reports 16 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07155174, a Phase 2 study of Small-cell Lung Cancer, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 2
Development phase
180 participants
Enrollment target
16
Study locations

Study Summary

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-706 given with atezolizumab, compared to standard of care (SOC) treatment (etoposide, carboplatin, atezolizumab, and optional lurbinectedin). ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are multiple treatment arms in this study. Participants will either receive ABBV-706 given with atezolizumab, at 1 of 2 doses, or SOC. Approximately 180 adult participants will be enrolled in the study across sites worldwide. In the safety lead-in, participants with SCLC will receive intravenous (IV) ABBV-706 in 1 of 2 doses with IV atezolizumab, or IV SOC. In the expansion portion of the study, participants with SCLC will receive IV ABBV-706 in 1 of 2 doses with atezolizumab, or IV SOC, until the optimal dose of ABBV-706 is determined. The estimated duration of the study is up to 69.5 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.

Conditions Studied

Small-cell Lung Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Atezolizumab
  • DRUG Etoposide
  • DRUG ABBV-706

Study Locations (16)

Other

  • Rambam Health Care Campus- Haifa /ID# 276663 - Haifa
  • Hadassah Medical Center-Hebrew University /ID# 276662 - Jerusalem
  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 277267 - Kaohsiung City
  • Taipei Veterans General Hospital /ID# 277263 - Taipei

Tokyo

  • Tokyo Metropolitan Komagome Hospital /ID# 277335 - Bunkyo Ku
  • National Cancer Center Hospital /ID# 277237 - Chuo-Ku

Connecticut

  • Yale University School of Medicine /ID# 278181 - New Haven

Florida

  • Ocala Oncology Center /ID# 278269 - Ocala

Indiana

  • Fort Wayne Medical Oncology And Hematology /ID# 277336 - Fort Wayne

Ohio

  • University Hospitals Cleveland Medical Center /ID# 277556 - Cleveland

Texas

  • The University of Texas MD Anderson Cancer Center /ID# 277929 - Houston

Central District

  • Meir Medical Center /ID# 277292 - Kfar Saba

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2025-11-25
Est. Completion 2031-09
Phase Phase 2

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07155174

The ClinicalTrials.gov registry entry for NCT07155174 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 230-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (22% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.

NCT07155174 reports 16 study locations spanning 12 distinct geographic areas - top geographies include Other, Tokyo, Connecticut.

Frequently Asked Questions

What is clinical trial NCT07155174 about?

NCT07155174 is a clinical study titled "A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer". Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-70...

What is the current status of trial NCT07155174?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2025-11-25. Estimated completion is 2031-09.

What conditions does trial NCT07155174 study?

This clinical trial studies the following conditions: Small-cell Lung Cancer.

What interventions are being tested in trial NCT07155174?

The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), Etoposide (DRUG), ABBV-706 (DRUG).

Who is sponsoring clinical trial NCT07155174?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07155174 being conducted?

This trial has 16 study locations across Connecticut, Florida, Indiana, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Small-cell Lung Cancer

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.